Thursday, January 26, 2012

#CISummit - Cancer Care.


Panel 3

Cancer: Journey Toward Better Health, Better Care and Lower Costs Case Study

Moderator: Simmi P. Singh

Senior Advisor, Health Innovation, Office of the Secretary, Department of Health and Human Services

Amy Abernethy, MD

Associate Professor, Division of Medical Oncology, Duke University School of Medicine and Medical Director of Oncology Quality, Outcomes and Patient-Centered Care in Duke University Health System

Amy Berman, RN

Program Officer, John A. Hartford Foundation 

Jeffrey Elton, PhD

Co-Founder and Board Member, Kew Group, Inc. 

Bruce Johnson, MD

Head of Thoracic Oncology, Dana Farber Cancer Institute 

Chris Olivia, MD

Board Member, Eviti, Inc.

Simmi Singh 

Cancer is 4th leading cause of death. 

Cancer = uncontroled cell reproduction.

Bruce Johnson - Dana Faber Cancer Institute

- How the Human Genome project has influenced cancer treatment.

- The past decade - what have we learned

The human genome was sequenced at the cost of $1B.
We can now sequence an individuals genome for $1,000.

Lung cancer is the most common form of cancer death. (156,940 in 2011 in USA)
85% of patients die.

Using the lessons from genome research is allowing pills targeting specific sub sets of cancer. This replaces chemo therapy or infusion with a simple pill that works for longer.

Jeffrey elton - Kew Group

Personalized Oncology Management in the community.

Quality based reimbursement+ Molecular diagnostics + Clinical Research

This is precision medicine.

Chris Olivia - Eviti

50% of cancer diagnostics are wrong. 

32-40% of treatments deviate from guidelines.

45% of patients don't take medications as prescribed.

Cancer has seen an explosion in data requirements to support cancer decision making.

Eviti can reduce approvals for treatment from days or weeks to 15m

Amy Abernathy - Duke University

Rapid Learning HealthCare - IOM in 2007 (but nothing happened.....)

Patient reported outcomes have been discarded as unreliable - how do we improve that so they can be relied upon.

Community oncologists are at the forefront of using patient reported outcomes.

Sequentially Link data connect disparate datasets. 

Data needs to be re-purposable.

Amy Berman - Hartford Foundation

Talking about her story about the diagnosis of her inflammatory breast cancer.

The message is that we have to consider the patient and their quality of life. 

Amy has chosen to not do the high cost, high impact procedures and instead preserve quality of life.

The patient needs to be able to make informed choices and the medical community needs to place value of the patients set of values.

The Discussion
20% of research pipeline in pharma and elsewhere is going in to oncology.

We spend $150-$200B on Cancer Treatment.

The increased specialization of cancer treatment raises issues in running clinical trials and treatment. 

Chris Olivia gives a hats off to the work of CMS to unleash data and drive innovation to effect change. 

BJ - we may need to come up with different method of practicing as we unravel the secrets of cancer in the genome. Let's hope our payment systems of the future don't prevent this adaptation.

Posted via email from ekivemark: pre-blogspot